Flotadores

Both preclinical and early clinical evidence support 2'-FL's role in IBD. Preclinical studies consistently show 2'-FL reduces intestinal inflammation and restores barrier integrity in DSS-colitis models by modulating gut microbiota and suppressing TLR4/NF-κB signaling. An open-label pilot trial in adults with ulcerative colitis demonstrated improved gut microbiota composition and gastrointestinal symptoms after 6 weeks of 2'-FL-containing formula. 2'-FL has been identified as a potential regulator of inflammation in IBD, and its prebiotic and immune-modulatory actions overlap directly with IBD pathophysiology.

Acemannan has been evaluated in exploratory clinical pilot work for IBD (Crohn's disease and ulcerative colitis), showing improvement in all enrolled patients. It also exerts prebiotic and mucosal-healing effects relevant to IBD pathophysiology. Whole Aloe vera gel (acemannan-containing) has shown benefit in a placebo-controlled UC trial.

Akkermansia muciniphila is a mucin-degrading gut bacterium that is consistently depleted in IBD patients. Preclinical studies demonstrate it ameliorates experimental colitis by restoring gut barrier function, reducing inflammatory cytokines, and modulating the gut microbiome. It is an emerging next-generation probiotic candidate for IBD.

ALA-rich oils reduce intestinal inflammation in animal colitis models and suppress pro-inflammatory cytokines in human colonic cell lines. Limited human data show some benefit as a dietary adjunct in IBD, though evidence is not as robust as for marine omega-3s.

Alginate and alginate oligosaccharides have been shown in animal models and preliminary human protocol evidence to ameliorate intestinal inflammation in IBD, particularly ulcerative colitis. The mechanism is microbiota-dependent, involving enrichment of Bifidobacterium animalis and altered bile acid metabolism. Human trial protocols have been registered.

Aloe vera gel has been studied in small RCTs for ulcerative colitis, with one placebo-controlled trial showing superiority over placebo for inducing remission. A 2013 systematic review of herbal therapies in IBD identified aloe vera gel as superior to placebo in UC. It has anti-inflammatory and immunomodulatory properties relevant to IBD pathophysiology.

Andrographis paniculata has been evaluated in two placebo-controlled RCTs for ulcerative colitis via its standardized extract HMPL-004, demonstrating superiority over placebo in inducing clinical remission and response. A 2013 systematic review of herbal IBD therapies confirms its placebo-controlled RCT evidence in UC.

Andrographolide, the primary active diterpene of Andrographis paniculata, has been tested in placebo-controlled RCTs in ulcerative colitis. The proprietary extract HMPL-004 (containing andrographolide) was superior to placebo in inducing remission and clinical response in UC in two RCTs. It suppresses multiple pro-inflammatory pathways including NF-κB and Th1/Th17 responses.

Anthocyanins are water-soluble plant pigments with documented anti-inflammatory effects in preclinical IBD models, including NF-κB inhibition and reduction of mucosal TNF-α and IL-6. They are found in berries, red cabbage, and other colorful fruits and are emerging subjects of IBD clinical research.

Qingdai (Indigo Naturalis) from S. cusia has multiple clinical studies supporting efficacy in ulcerative colitis, one form of IBD. A 2024 RCT showed mucosal healing and clinical remission comparable to Adisa, and earlier open-label and prospective studies confirmed 1-year efficacy and safety.

Multiple preclinical studies show Atractylodes macrocephala extracts, polysaccharides, and volatile oils alleviate experimental colitis in rodent models by reducing inflammation, restoring gut barrier function, and modulating microbiota. Animal evidence suggests efficacy potentially superior to sulfasalazine for preventing colitis relapse.

B. coagulans has been assessed in IBD patients in a randomized controlled trial, showing good GI tract survival and modulation of serum cytokines, serotonin, and dopamine. Animal evidence and clinical evidence from IBS studies also support anti-inflammatory effects relevant to IBD. The evidence base is emerging but not yet large-scale.

Preclinical studies and mechanistic reviews support berberine from barberry as an anti-inflammatory agent in IBD, acting by modulating gut microbiota, protecting intestinal barrier integrity, and suppressing pro-inflammatory signaling. Clinical trials for ulcerative colitis remission maintenance are registered (NCT02962245). Evidence in humans is emerging.

Berberine is an isoquinoline alkaloid found in several plants including Coptis chinensis and Berberis species with preclinical and emerging clinical evidence for IBD, particularly UC. It reduces NF-κB-driven colonic inflammation, reshapes gut microbiota, and has been used in traditional Chinese medicine for GI inflammatory conditions.

Beta-glucan has shown anti-inflammatory activity in IBD-relevant mechanisms including gut microbiota modulation, butyrate production, and autophagy flux induction in intestinal epithelial cells. Clinical case reports in ulcerative colitis patients demonstrate improvements in Mayo score, fecal calprotectin, and inflammatory biomarkers following dietary beta-glucan intervention. Evidence is preliminary but biologically coherent.

Bifidobacterium species have strong clinical evidence for IBD, particularly UC, with systematic reviews identifying them among the most effective probiotic choices for induction and maintenance of remission. Bifidobacterium-containing preparations show significantly higher UC remission rates vs. placebo in multiple RCTs.

Bifidobacterium adolescentis is a major butyrate-producing Bifidobacterium species that is depleted in IBD patients. Its supplementation has been studied in clinical IBD contexts, with evidence supporting gut microbiota restoration and anti-inflammatory effects.

Bifidobacterium animalis (including subsp. lactis) is a well-studied probiotic with clinical evidence in UC. It has been evaluated in IBD RCTs and produces SCFAs that directly alleviate intestinal inflammation and support mucosal integrity.

Bifidobacterium bifidum has demonstrated clinical efficacy in UC in RCTs. It significantly reduced clinical colitis activity indices, improved mucosal histology, and maintained remission in UC patients in controlled trials. It is among the Bifidobacterium strains with strongest evidence in IBD.

Bifidobacterium breve has been evaluated in clinical trials for both UC and CD, demonstrating efficacy in remission maintenance and as adjunctive therapy. It is an important species in pediatric IBD given its prominence in infant gut microbiota.

Bifidobacterium infantis 35624 has been studied specifically in IBD and IBS, demonstrating significant immunomodulatory effects including normalization of the IL-10/IL-12 ratio and reduction of systemic and mucosal inflammatory markers in UC patients in controlled trials.

Bifidobacterium lactis is a well-studied probiotic strain with clinical evidence in UC, where it has been used in both standalone and combination probiotic formulations demonstrating improved clinical and endoscopic outcomes in IBD trials.

Bifidobacterium longum has one of the strongest clinical evidence bases among Bifidobacterium species in IBD. Synbiotic preparations combining B. longum with prebiotics have demonstrated significant improvement in endoscopic and histological scores in UC in randomized trials.

Human pilot clinical data show that anthocyanin-rich bilberry preparation significantly reduced disease activity, fecal calprotectin, and mucosal inflammation in mild-to-moderate UC over 6 weeks. Molecular studies confirm modulation of NF-κB, IFN-γ, and TNF-α signaling in colonic tissue of treated patients. Evidence is preliminary but derives from human clinical data.

Bile acid absorption is altered in both Crohn's disease and ulcerative colitis, with IBD patients consistently showing reduced bile salt biotransformation gene abundance and lower secondary bile acid levels versus healthy controls. Bile acid malabsorption is a recognized complication of ileal IBD, contributing to diarrhea. The gut-liver bile acid axis and FXR signaling are implicated in mucosal immune regulation relevant to IBD pathophysiology.

Ulcerative colitis patients are included in a CRP meta-analysis showing significant anti-inflammatory effects with N. sativa. The PMC GI review documents experimental evidence for anti-colitic effects. Clinical and experimental evidence together support N. sativa's role in IBD-associated inflammation.

Boswellia serrata gum resin has been evaluated in multiple small RCTs for IBD, showing efficacy in ulcerative colitis and Crohn's disease comparable in some trials to mesalazine. Its active boswellic acids inhibit 5-lipoxygenase and leukotriene synthesis, key inflammatory pathways in IBD. It has traditional use in Ayurvedic medicine for inflammatory gut conditions.

Boswellic acids are the active pentacyclic triterpenoids in Boswellia serrata resin with demonstrated IBD-relevant anti-inflammatory mechanisms and clinical trial evidence in UC and Crohn's disease. They are the primary mediators of Boswellia's therapeutic effects, acting via 5-LOX inhibition and NF-κB suppression.

Bromelain has significant preclinical and emerging clinical evidence in IBD, including a study showing marked reduction in IBD development in IL-10-knockout mice and clinical improvement signals in ulcerative colitis patients. It blocks TNF-α receptors, suppresses NF-κB, and reduces pro-inflammatory cytokines relevant to IBD pathophysiology. A 2025 RCT specifically assessed bromelain in UC disease activity and quality of life.

Butyrate supplementation, including tributyrin, has been evaluated as an adjunct in IBD. Multiple human RCTs using oral butyrate show reductions in inflammatory markers (fecal calprotectin, CRP) and disease activity scores in UC and Crohn's disease. Results are mixed—a pediatric multicenter RCT showed no benefit while a unicentric pediatric RCT showed significant remission advantage. Tributyrin specifically has animal-model support for colitis; direct human IBD tributyrin RCTs are still emerging.

Butyric acid is a short-chain fatty acid (SCFA) that serves as the primary energy source for colonocytes and plays a central role in maintaining intestinal barrier integrity. It has been tested in clinical trials for ulcerative colitis, with evidence supporting mucosal healing and anti-inflammatory effects in IBD.

Red cabbage extract has attenuated experimental colitis in mouse IBD models. The anti-inflammatory compounds in cabbage (anthocyanins, glucosinolates, SCFAs from microbiome modulation) address multiple IBD pathological mechanisms including barrier dysfunction, dysbiosis, and NF-κB-driven inflammation. Human clinical data are preclinical-to-emerging.

BCP has demonstrated consistent preclinical efficacy in IBD models through dual CB2/PPARγ activation, reducing intestinal inflammation, oxidative damage, and pathogen burden. The 2011 Am J Pathol colitis study is the foundational reference.

Cat's Claw (Uncaria tomentosa) contains oxindole alkaloids with NF-κB inhibitory and anti-inflammatory properties studied in IBD-relevant models. Traditional use in Amazonian medicine includes inflammatory bowel conditions, and some clinical and preclinical data support its IBD-relevant anti-inflammatory activity.

Catalase activity in erythrocytes and immune cells is significantly reduced in active IBD (both Crohn's disease and ulcerative colitis) compared to healthy controls, as confirmed by a systematic review and meta-analysis. Catalase has diagnostic utility as a biomarker of IBD activity, with activity inversely correlating with disease severity.

Catechins exert anti-inflammatory, antimicrobial, and gut microbiota-modulating effects relevant to IBD. A PMC review concluded catechins may have a dual role in IBD disease management, and human trials support flavonoid (catechin-containing) intake in reducing gut inflammation and pathogenic bacterial growth.

Inulin from chicory has been studied in IBD (ulcerative colitis and Crohn's disease) for its anti-inflammatory and microbiota-modulating prebiotic effects. Small human studies have found reduced symptoms in ulcerative colitis and reduced inflammatory markers in Crohn's disease, supported by in vitro and animal evidence showing inulin suppresses pro-inflammatory cytokines and prevents IBD progression.

A 2022 peer-reviewed animal study (Am J Physiol Gastrointest Liver Physiol) found oral chlorophyllin attenuated DSS-induced colitis in mice, reducing intestinal epithelial damage, inflammatory cell infiltration, body weight loss, and mortality. The mechanism involves suppression of overactivated autophagy via Akt/mTOR pathway activation and reduction of endoplasmic reticulum stress. Human clinical trials for IBD have not been completed.

Bovine colostrum contains immunoglobulins, growth factors (including EGF and IGF-1), lactoferrin, and antimicrobial peptides that may promote intestinal mucosal healing and modulate immune responses in IBD. A 2013 systematic review of herbal/natural therapies in IBD noted bovine colostrum may be efficacious in UC.

A double-blind double-dummy RCT demonstrated that Myrrhinil-Intest® (myrrh + chamomile + coffee charcoal) was non-inferior to mesalazine for maintaining remission in ulcerative colitis. Mechanistic cell studies confirm myrrh restores intestinal epithelial barrier function impaired by IBD-relevant cytokines.

Coptis chinensis is a traditional Chinese medicinal herb and the primary plant source of berberine, with extensive use in TCM for inflammatory intestinal conditions including dysentery and enteritis. Its IBD evidence derives largely from its berberine content and systematic pharmacological studies targeting IBD inflammatory pathways.

Curcuma (Curcuma longa/Curcuma species) is the turmeric genus from which curcumin is derived. Multiple clinical trials and a 2025 meta-analysis demonstrate Curcuma's principal bioactive (curcumin) has significant efficacy in achieving clinical remission and response in UC patients when used adjunctively with standard therapy.

Curcumin has been tested in 13 placebo-controlled RCTs in IBD, with a 2025 meta-analysis demonstrating significant efficacy in achieving clinical remission and response in ulcerative colitis patients when used as adjunctive therapy. It targets NF-κB, oxidative stress, and gut microbiota modulation relevant to IBD. Evidence in Crohn's disease is inconclusive.

DHA is an omega-3 fatty acid from marine sources studied in combination with EPA for IBD management. Clinical evidence shows combined EPA/DHA reduces CD relapse. DHA alone showed protective associations with Crohn's disease in longitudinal cohort data.

Both Crohn's disease and ulcerative colitis within IBD are associated with reduced intestinal mucosal DAO activity, and serum DAO is studied as a biomarker of small intestinal permeability and mucosal integrity in IBD patients. Low DAO in IBD reflects enterocyte damage and can contribute to secondary histamine intolerance.

DHA demonstrates anti-inflammatory and mucosal protective effects in experimental colitis models, reducing pro-inflammatory cytokines, oxidative stress, and improving intestinal barrier function. A large prospective cohort study (n=229,702 from 9 European centers) found high dietary DHA intake inversely associated with Crohn's disease incidence.

DPA is a precursor to SPMs (resolvins, protectins, maresins) that actively resolve intestinal inflammation, and DPA supplementation altered gut microbiota and metabolomes in a UC mouse model toward protective profiles. Broader n-3 PUFA evidence in IBD implicates DPA as a constituent of effective fish-oil interventions. Direct human IBD trials isolating DPA are not yet available.

EPA has been studied in ulcerative colitis and Crohn's disease, with Mendelian randomization data showing genetically higher EPA concentrations are causally associated with reduced IBD risk (OR 0.78). EPA reduces intestinal inflammation by modulating mucosal eicosanoid profiles and pro-inflammatory cytokines.

EPA is the omega-3 fatty acid most directly associated with reduced IBD risk in Mendelian randomization studies, and has been clinically investigated for reducing Crohn's disease relapse. It reduces LTB4 and prostaglandin E2 production in colonic mucosa, key mediators of IBD inflammation.

Fennel seed extract has been studied in vitro for IBD-relevant mechanisms: it improves intestinal epithelial barrier function and modulates the STAT/JAK inflammatory pathway in colonic cell models. Fennel is used as a complementary treatment for IBD in Iran. Human IBD-specific trials are not available.

Fish oil, as a source of EPA and DHA, has been studied in multiple clinical trials for both UC and CD, and is among the most commonly used CAM supplements by IBD patients. It reduces mucosal LTB4 and prostaglandin E2 levels and has demonstrated benefit in CD relapse prevention in clinical trials.

Flaxseed is a rich source of alpha-linolenic acid (ALA, an omega-3 fatty acid), lignans, and mucilaginous fiber with preclinical evidence for reducing intestinal inflammation in IBD models. It modulates gut microbiota and provides SCFAs relevant to mucosal healing in IBD.

Fructooligosaccharides are prebiotic fibers that selectively stimulate beneficial gut bacteria, particularly Bifidobacteria and Lactobacilli, which are depleted in IBD. Clinical trials in Crohn's disease have shown FOS supplementation can increase fecal Bifidobacteria and modestly improve clinical disease activity indices.

Fulvic acid's anti-inflammatory mechanisms (TNF-α suppression, COX-2 inhibition) and gut barrier-restorative properties are directly relevant to IBD pathology. Animal studies confirm reduced gut inflammation, though human RCTs are absent.

N-acetylglucosamine (NAG), a closely related acetylated form of glucosamine, has been investigated in IBD based on the finding that IBD patients show reduced incorporation of glucosamine into intestinal mucosa glycosaminoglycans. A pediatric pilot study and an open-label adult clinical trial (n=34, 6 g/day for 4 weeks) reported symptom improvement in the majority of participants. Animal models show glucosamine and NAG reduce intestinal inflammation, improve gut barrier function, and modulate inflammatory cytokines. Evidence remains preliminary, with no large randomized controlled trials completed.

Green chiretta extract HMPL-004 is the most clinically studied herbal extract in ulcerative colitis, with two published RCTs demonstrating efficacy versus placebo and comparability to mesalamine. Its NF-κB inhibitory and Th1/Th17-suppressive mechanisms are directly relevant to IBD pathophysiology.

Preclinical evidence from animal IBD models shows that the lipid-rich supercritical extract of P. canaliculus may exert gastroprotective effects, reducing colonic inflammation markers and improving intestinal morphology in chemotherapy-induced mucositis models. Human studies of GLM use in OA patients demonstrate that whole GSM extract improved gastrointestinal symptoms in patients concurrently taking anti-inflammatory medications. Direct human RCT evidence in IBD patients is not yet published; evidence remains at animal/mechanistic and indirect clinical levels.

H. antidysenterica is documented as useful adjunctive therapy for IBD in peer-reviewed literature. Both preclinical (DNBS-induced rat colitis) and one small human clinical trial in ulcerative colitis support its anti-inflammatory action on the bowel mucosa. Conessine and flavonoids are implicated in suppressing mucosal oxidative stress.

A 2025 preclinical study in Advanced Science demonstrated that honeysuckle-derived nanovesicles alleviate IBD symptoms, reduce colonic inflammation, modulate gut microbiota, and regulate bile acid metabolism. A 2024 study found honeysuckle MIR2911 reduces pathogenic bacteria and improves colitis via gut microbiota regulation. PMC reviews highlight honeysuckle's emerging role in IBD management.

SBI has been evaluated as adjunct nutritional therapy in IBD patients refractory to standard treatment. Retrospective chart reviews show symptom improvement in patients with Crohn's disease and ulcerative colitis. A 2024 PMC study also confirmed that SBI alters gut microbiota diversity in IBD patients in a favorable direction.

A PMC-indexed animal study evaluated bael unripe fruit extract specifically in IBD models (acetic acid-induced ulcerative colitis and indomethacin-induced enterocolitis in rats), finding dose-dependent reductions in disease activity index, macroscopic and microscopic inflammation scores, and mast cell degranulation. Traditional use of bael in dashmula formulations targets colitis and dysentery.

Clinical evidence supports Boswellia serrata's role in both major IBD subtypes — ulcerative colitis and Crohn's disease — though with variable effect sizes. The mechanism involves 5-LOX inhibition reducing pro-inflammatory leukotrienes, NF-κB suppression, and protection of intestinal epithelial barrier integrity. Three small clinical trials were collectively found clinically effective by a 2008 systematic review.

Indigo naturalis (IN) has the strongest evidence base among herbal remedies for IBD, with multiple published RCTs in ulcerative colitis and extensive animal-model data. A 2025 Frontiers in Pharmacology meta-analysis of 15 animal studies and multiple human RCTs confirm clinically meaningful effects. Mechanism involves AhR activation, IL-22 induction, and gut microbiota modulation.

Inulin is a prebiotic fructan that selectively promotes growth of beneficial gut bacteria including Bifidobacterium, which are reduced in IBD. Clinical studies in Crohn's disease and UC demonstrate that inulin supplementation can improve fecal microbiota composition and reduce inflammatory markers.

Iron deficiency anemia (IDA) is the most common systemic complication of IBD, arising from chronic intestinal blood loss, malabsorption, reduced dietary intake, and inflammation-driven hepcidin upregulation. European Crohn's and Colitis Organisation (ECCO) guidelines mandate screening and treatment of IDA in IBD patients. Intravenous iron formulations—particularly ferric carboxymaltose and iron sucrose—are preferred in active disease because oral iron has limited absorption and may exacerbate intestinal inflammation.

IMO has been explored for IBD based on its ability to restore SCFA-producing bacteria, support tight junction integrity, and reduce mucosal inflammation in preclinical colitis models. The 2024 PMC review identifies IBD as a key therapeutic target for IMO. Human clinical data in IBD populations are not yet available.

Multiple animal model studies demonstrate jujube polysaccharides and extracts reduce IBD-associated inflammation by suppressing NF-κB/JAK1/STAT3 pathways, restoring intestinal barrier integrity, and modulating gut microbiota. Jujube is considered a promising natural candidate for IBD management based on preclinical data, but human trials are absent.

In vitro studies show krill oil dose-dependently reduces LPS-induced IL-1β and TNFα in human macrophages via NF-κB pathway suppression. Animal UC models show krill oil attenuates colonic inflammation and oxidative stress. A 2024 PMC systematic review concluded krill oil has potential therapeutic benefits in IBD prevention, though no human clinical trials in IBD patients have been published.

Glutamine, delivered as the AG dipeptide, has been applied in IBD management based on its gut-trophic and immunomodulatory properties. A systematic review of clinical trials confirmed glutamine supplementation has been applied in IBD practice, though human RCT results are mixed. Preclinical evidence with specific AG formulations in DSS and TNBS colitis models is consistent and robust.

L-glutamine is an amino acid serving as the primary fuel source for intestinal enterocytes and colonocytes, and is critical for maintaining gut barrier integrity. Preclinical and some clinical data support its role in reducing intestinal permeability and mucosal inflammation in IBD, particularly in Crohn's disease.

Lactiplantibacillus plantarum (formerly Lactobacillus plantarum) has clinical trial evidence in IBD, demonstrating anti-inflammatory effects in UC including reduced mucosal TNF-α and IL-6, improved intestinal barrier function, and clinical remission support.

Lactobacillus acidophilus is among the most studied probiotic strains in IBD. As part of probiotic combinations (VSL#3, multi-strain products), it has shown strong evidence for induction and maintenance of remission in mild-to-moderate UC, and is included in major IBD probiotic clinical trials.

Lactobacillus brevis is a lactic acid bacterium with evidence from clinical IBD studies, particularly as part of multi-strain probiotic formulations. Clinical trials have shown that probiotic mixtures containing L. brevis can improve remission rates and inflammatory markers in UC patients.

L. bulgaricus is a constituent of VSL#3, which has demonstrated clinical benefit in mild-to-moderate ulcerative colitis across multiple RCTs. L. bulgaricus and L. casei have been shown to significantly lower TNF-α in colonic mucosal samples from Crohn's disease patients. Evidence for the broader IBD category is established via multi-strain preparations and mucosal biopsy data.

Lactobacillus casei has demonstrated clinical utility in UC in multiple RCTs, both as a standalone probiotic and in combination products. It has been shown to maintain remission in UC, improve intestinal barrier function, and reduce mucosal inflammatory markers including TNF-α and IL-6.

Lactobacillus fermentum is a lactic acid bacterium with evidence from clinical IBD studies as part of multi-strain probiotic products. It contributes to gut microbiota restoration and anti-inflammatory effects important in UC management.

Lactobacillus gasseri is among the Lactobacillus species studied in IBD clinical trials. As a component of multi-strain probiotic preparations for UC, it has contributed to improved clinical outcomes, microbiota normalization, and reduced mucosal inflammatory activity.

Lactobacillus paracasei has shown anti-inflammatory activity in IBD models and clinical studies, improving UC activity indices and modulating gut microbiota. It is included in clinical multi-strain probiotic IBD formulations with demonstrated efficacy.

Preclinical data and some clinical evidence support L. plantarum's role in IBD management through immune modulation, gut microbiota restoration, and mucosal barrier reinforcement. Clinical human evidence remains limited and further RCTs are needed.

Lactobacillus reuteri has shown clinical efficacy in pediatric and adult IBD studies, particularly UC, with evidence from RCTs demonstrating reduced clinical activity scores, improved mucosal healing, and anti-inflammatory cytokine modulation.

Lactobacillus rhamnosus GG (LGG) is one of the best-studied probiotic strains in IBD. Multiple clinical trials demonstrate its efficacy in UC remission maintenance and as adjunct therapy, with LGG listed among the most commonly used probiotics in IBD RCTs.

Lactobacillus salivarius has been studied in IBD clinical trials as part of multi-strain probiotic formulations showing efficacy in UC, with immunomodulatory and barrier-protective effects relevant to IBD pathophysiology.

Lactococcus lactis has been studied in IBD, particularly as part of probiotic combinations for UC. Engineering strains to deliver anti-inflammatory molecules such as IL-10 directly to the gut mucosa represents one of the most novel therapeutic applications for IBD studied in clinical trials.

Lactoferrin has dual evidence in IBD: as a validated fecal biomarker for disease activity and as an emerging therapeutic modulator of mucosal immunity. Clinical trials in children with IBD-related iron-deficiency anemia show lactoferrin outperforms ferrous sulfate. Animal and early human data support anti-inflammatory therapeutic potential.

The clinical evidence for lecithin in IBD is concentrated specifically in ulcerative colitis (UC), where multiple RCTs demonstrate therapeutic benefit via phosphatidylcholine supplementation to the colonic mucus layer. Evidence for Crohn's disease is lacking. The UC evidence is the same body of research as under Colitis.

Bioactive compounds from L. edodes mycelia, including lentinan, AHCC, LEM, and MSCE, show anti-inflammatory and mucosal-protective effects in cell and animal models of IBD. These fractions restore gut microbiome heterogeneity, improve gut barrier function, and reduce pro-inflammatory cytokines. Human clinical trials in IBD specifically have not been published.

D-limonene demonstrates anti-inflammatory effects relevant to IBD in multiple preclinical colitis models, targeting NF-κB, MAPK, MMP-2/9, and Th1/Th2 cytokine pathways. Both ulcerative colitis and antinociceptive colitis models show efficacy. Immunomodulatory suppression of T-cell cytokine production is also documented in vitro. Evidence is entirely preclinical.

Multiple animal studies show Lion's Mane extracts reduce colonic inflammation, improve histological scores, modulate gut microbiota, and suppress NF-κB signaling in TNBS- and DSS-induced IBD models. An ex vivo study on human IBD tissue also showed reduced inflammatory burden. Clinical human trials in IBD patients are not yet available.

Digestive enzyme blends including lipase have been tested in IBD patients with overlapping IBS symptoms. A controlled trial in 43 IBD-IBS patients found that adding a digestive enzyme supplement to standard therapy reduced bloating, flatulence, and abdominal pain. Additionally, EPI can develop secondary to IBD, creating a clinical rationale for lipase supplementation in a subset of IBD patients.

Luteolin significantly alleviates experimental colitis in preclinical models by modulating T cell differentiation, inhibiting NF-κB-driven inflammatory mediators, and improving gut microbiota structure. A systematic review and meta-analysis of preclinical evidence supports its therapeutic potential in ulcerative colitis.

In vitro studies on colonic epithelial cells (HT-29) and in vivo TNBS-induced Crohn's disease mouse models demonstrate that maqui polyphenol extract exerts antioxidant and anti-inflammatory effects in the gut, with a synergistic effect alongside 5-ASA. The evidence is preclinical only; no human IBD clinical trial for maqui exists.

Preliminary human RCTs and multiple animal studies support mastic gum as an adjunct in IBD (Crohn's disease and ulcerative colitis). A pilot clinical study (10 patients with active Crohn's disease, 2.2 g/day for 4 weeks) found significant reductions in IL-6 and CRP. A 2019 RCT (60 IBD patients, 2.8 g/day for 3 months) found reduced fecal lysozyme versus placebo, indicating lower disease activity.

MCTs are routinely incorporated into enteral nutrition formulas for IBD patients because they do not require bile salts or pancreatic lipase for absorption, are absorbed directly via portal circulation, and provide calories when fat malabsorption is limiting. Clinical guidelines from the University of Virginia GI Nutrition program recommend MCT oil (up to 50 g/day in divided doses) as a calorie supplement in IBD-related malabsorption.

M. officinalis root extracts have demonstrated efficacy in reducing colitis severity in dextran sodium sulfate (DSS)-induced chronic ulcerative colitis mouse models, reducing pro-inflammatory cytokines and regulating T lymphocyte apoptosis. The relevant iridoid monotropein from M. officinalis roots has also been shown to attenuate NF-κB-mediated colitis.

Mucin barrier dysfunction—including altered goblet cell secretion and MUC2 structural changes—is a hallmark of IBD pathogenesis documented in clinical and experimental studies. IBD patients display defects in mucus layer composition that contribute to increased intestinal permeability and chronic inflammation. Changes in intestinal permeability correlate clinically with IBD disease course.

Myrrh is an active component of Myrrhinil-Intest, a licensed German herbal product with clinical trial evidence for IBD, specifically ulcerative colitis remission maintenance. Mechanistic studies show myrrh reduces intestinal inflammation and stabilizes the epithelial barrier. Both clinical and laboratory evidence support this relationship.

N-acetyl glucosamine (NAG) has been studied in pediatric Crohn's disease and experimental IBD, where it may reduce intestinal inflammation, support glycosaminoglycan synthesis in the gut mucosa, and improve mucosal healing. It is incorporated in IBD supplement formulations.

N-acetyl cysteine is a precursor to glutathione, the principal endogenous antioxidant, and has been studied in IBD for its ability to reduce oxidative stress and mucosal inflammation. Clinical and preclinical evidence supports its role in reducing NF-κB activation and oxidative damage in colonic tissue relevant to IBD.

OA reduces intestinal inflammation and restores mucosal barrier integrity in DSS-induced colitis models by rebalancing Th17/Treg cells, suppressing NF-κB, and upregulating tight junction proteins. These findings are consistent across several independent studies.

Omega-3 fatty acids, particularly EPA and DHA, have been studied in multiple clinical trials for IBD. EPA is associated with decreased IBD risk in Mendelian randomization studies, and EPA/DHA supplementation has been reported to reduce clinical relapse rates in Crohn's disease. They exert anti-inflammatory effects by competing with arachidonic acid in eicosanoid synthesis.

Preclinical evidence strongly supports pectin's beneficial effects in IBD models, including reduced colonic inflammation, improved SCFA production, and microbiota rebalancing. Clinical trial data specific to pectin in IBD patients are currently limited, representing a gap between preclinical promise and clinical validation.

PC modulates gut barrier function, macrophage polarization, and gut microbiota structure in IBD. The strongest clinical evidence is in ulcerative colitis; Crohn's disease evidence is more limited. PC has been studied as both a therapeutic agent and drug carrier in IBD.

Bromelain has been studied in IBD with encouraging animal and in vitro data, and a 2025 RCT found bromelain supplementation significantly improved disease activity and quality of life in ulcerative colitis patients. Mechanisms include TNFR inhibition, NF-κB suppression, and reduction of pro-inflammatory cytokines.

Plantago ovata (psyllium/ispaghula husk) seeds were shown to be as effective as mesalazine for maintaining UC remission in a landmark clinical trial, making Plantago one of the best-evidenced natural agents in IBD. It provides prebiotic fiber, increases colonic butyrate, and supports gut microbiota normalization.

Plantago ovata seeds were compared head-to-head against mesalamine in a randomized clinical trial for maintaining remission in ulcerative colitis. P. major was reported helpful in a case of refractory ulcerative pancolitis. Psyllium fiber is protective against experimental colitis and modulates gut microbiota and intestinal barrier—both central IBD mechanisms.

Clinical studies documented improved clinical response in IBD patients when pomegranate extract was taken as a complement to standard medications. Preclinical work in DSS-colitis mouse models confirms pomegranate extract reduces gut biofilm-forming bacteria and promotes intestinal mucosal healing.

Fecal propionate levels are reduced in IBD patients. Propionate ameliorates experimental colitis in animal models by improving intestinal barrier function, reducing inflammatory cytokine production (TNF-α, IL-1β, IL-6), and regulating macrophage polarization toward anti-inflammatory phenotypes via GPR43/HDAC1/IL-10 pathways. Increasing fermentable fiber intake to promote SCFA production is considered clinically beneficial in colitis management.

Psyllium is a soluble fiber prebiotic with clinical evidence in IBD, particularly UC, where Plantago ovata seeds (the psyllium source) were found as effective as mesalazine for maintaining UC remission in a clinical trial. It supports gut microbiota, butyrate production, and intestinal transit.

Quercetin is a flavonol with extensive preclinical evidence for IBD, inhibiting NF-κB, reducing pro-inflammatory cytokines, protecting intestinal epithelial barrier integrity, and modulating gut microbiota. Clinical evidence is emerging but primarily based on preclinical and in vitro data with some human study support.

A murine DSS-induced colitis model found quinoa whole-grain diet reduced disease activity index, histological damage, and gut microbiota dysbiosis associated with IBD. Quinoa polysaccharides and peptides consistently reduced pro-inflammatory markers across multiple preclinical models. Human IBD-specific clinical evidence for quinoa is absent; the evidence is preclinical.

Reishi has documented anti-ulcer, anti-inflammatory, and prebiotic properties in preclinical models relevant to IBD. Gut microbiome rebalancing, NF-κB and NLRP3 inflammasome suppression, and intestinal barrier protection are established preclinical mechanisms. Traditional Chinese medicine used reishi for gastrointestinal inflammatory conditions. No human RCTs specific to IBD have been published.

A meta-analysis of 30 RCTs (2,475 patients) found rhubarb-based therapy for UC increased clinical efficacy, reduced recurrence, and outperformed 5-aminosalicylic acid alone. Rhein modulates gut microbiota to alleviate experimental colitis. Multiple systematic reviews support rhubarb's IBD-relevant anti-inflammatory and microbiome-modulating mechanisms.

Rosmarinic acid has demonstrated anti-colitis activity in multiple preclinical IBD models (DSS-induced and TNBS-induced colitis), reducing colon inflammation, mucosal damage, and inflammatory cytokine levels via NF-κB and MAPK pathway suppression. The 2020 Frontiers in Pharmacology review explicitly identifies colitis as a primary disease target for RA's anti-inflammatory effects.

A 2025 systematic review and meta-analysis (PMC) of preclinical studies found rutin significantly alleviated IBD inflammatory markers, with efficacy comparable to positive control drugs sulfasalazine and budesonide. A clinical trial in UC patients using a rutin-enriched extract showed comparable outcomes to mesalazine.

Saccharomyces boulardii is a probiotic yeast with pilot study evidence for efficacy in UC and Crohn's disease. It has demonstrated clinical benefit in UC as add-on therapy to mesalazine and reduced stool frequency in CD. Mechanistically, it controls intestinal inflammation via dendritic cell modulation and NF-κB inhibition.

Laboratory studies have demonstrated antioxidant activity of slippery elm in tissue from IBD patients comparable to 5-aminosalicylic acid. A PMC review and the Saudi Journal of Gastroenterology confirm these antioxidant findings in IBD patient tissue. Human clinical trials are lacking, but the ex vivo tissue evidence constitutes preliminary scientific evidence.

S. flavescens-derived oxymatrine has been used to treat IBD in China and is the subject of a 2025 systematic review and meta-analysis of preclinical studies. Multiple clinical studies suggest Kushen extract formulations demonstrate efficacy in IBD patients. Evidence spans both ulcerative colitis and Crohn's-relevant inflammatory pathways.

SPM levels are reduced in intestinal tissue and serum of both UC and Crohn's disease patients. Human ex vivo studies demonstrate that resolvin D2 reduces mucosal cytokine production in CD patient biopsies. SPMs are actively being evaluated as translational therapeutics for IBD.

Stigmasterol modulates IBD-relevant immune pathways including Treg/Th17 balance, gut microbiota composition, and SCFA production. Preclinical DSS-colitis mouse data support its anti-IBD activity, with partial confirmation using human patient-derived T cells.

S. thermophilus, as part of the VSL#3 probiotic mixture, has demonstrated clinical efficacy in IBD including ulcerative colitis and pouchitis. Evidence also exists from preclinical models showing reduced colitis signs and improved intestinal barrier function. Human clinical evidence for S. thermophilus in Crohn's disease specifically is limited to its role within multi-strain formulations.

Sulforaphane reduces IBD-relevant mucosal inflammation through Nrf2 activation, NF-κB suppression, gut barrier restoration, and microbiome remodeling in animal models. PMC reviews cite human clinical trial data for GI inflammatory conditions. Multiple SFN mechanisms directly address IBD pathophysiology.

Two published preclinical studies demonstrated that P. paniculata extract significantly reduced intestinal inflammation in TNBS-induced colitis in rats, reducing macroscopic injury, pro-inflammatory cytokines, and oxidative stress markers. Modulation of MAPK and mucin gene expression pathways was identified as a mechanism.

Sweet Annie (Artemisia annua) and wormwood (Artemisia absinthium) are closely related Artemisia species. Wormwood (Artemisia absinthium) has been specifically tested in placebo-controlled clinical trials for Crohn's disease, demonstrating significant reduction in TNF-α and improvement in CDAI scores. Traditional use of Artemisia species for GI inflammation spans multiple medical traditions.

A substantial body of preclinical research demonstrates artemisinin and its derivatives reduce IBD hallmarks including colonic inflammation, oxidative stress, intestinal barrier disruption, and dysbiosis in rodent models. A 2025 review in Acta Pharmacologica Sinica comprehensively documents multitarget artemisinin activity in IBD.

IBD including Crohn's disease and ulcerative colitis involves disrupted butyrate metabolism and colonic barrier dysfunction, both addressable by tributyrin. Butyrate supplementation trials in IBD show adjunct benefits in disease activity and mucosal healing. Tributyrin specifically has been investigated in ileocecal resection models relevant to Crohn's disease, with effects on inflammation and microbial recolonization.

Turmeric (Curcuma longa) is the plant source of curcumin, with 13 placebo-controlled RCTs in IBD supporting its use, particularly in UC. As a whole herb, turmeric also contains essential oils, turmerones, and other curcuminoids with synergistic anti-inflammatory effects. A 2025 meta-analysis confirms significant efficacy in UC clinical remission.

Preclinical and mechanistic studies show UA reduces intestinal inflammation relevant to IBD by strengthening the epithelial barrier, inhibiting NF-κB in gut-resident immune cells, and upregulating tight junction proteins via AhR-Nrf2 pathways. Ellagitannin-rich foods have documented benefits in IBD, with UA as the proposed active metabolite. Dedicated human IBD RCTs are not yet published.

Vitamin D deficiency is consistently associated with increased IBD risk, disease severity, and relapse rates in both UC and CD. Vitamin D supplementation has been studied in IBD clinical trials, with evidence suggesting it may help maintain remission in CD and reduce inflammatory markers in IBD patients.

Vitamin D3 (cholecalciferol) is the most bioavailable form of vitamin D and is specifically studied in IBD clinical trials. Deficiency is prevalent in IBD patients and associated with disease activity; D3 supplementation reduces inflammatory markers and may maintain CD remission in clinical trials.

Wheat-derived arabinoxylan and wheat bran polyphenols have shown protective effects against experimental colitis in animal models via modulation of gut microbiota, suppression of NF-κB/MAPK inflammatory pathways, and increased regulatory T cells. Current IBD clinical practice guidelines encourage dietary fiber supplementation (including from wheat) during remission to prevent relapse. Direct human RCT evidence for wheat specifically in IBD remains limited.

The strongest human clinical evidence for wheatgrass is in ulcerative colitis (a form of IBD). A randomized double-blind placebo-controlled trial found 100 mL/day of wheatgrass juice for one month significantly reduced overall disease activity and rectal bleeding severity. A 2025 meta-analysis of polyphenol RCTs in ulcerative colitis included wheatgrass juice as an effective agent for inducing clinical remission.

XOS demonstrates benefits in IBD-relevant models by improving gut barrier function, increasing tight junction protein expression, and enriching beneficial bacteria depleted in both Crohn's disease and ulcerative colitis. In vitro and animal studies are promising; direct human RCT data in IBD remain limited.

Zinc deficiency is highly prevalent in IBD, affecting approximately one-third of the overall IBD population and up to 45% in some cohorts. Deficiency is most common in Crohn's disease due to impaired small-intestinal absorption. Zinc exerts anti-inflammatory effects via NF-κB inhibition, supports intestinal epithelial repair, and modulates the gut microbiota. Clinical trial evidence for supplementation remains preliminary but supports correcting deficiency to improve disease severity.

Calendula preparations have a documented traditional role in IBD management, especially ulcerative colitis, supported by an animal model study demonstrating mucosal healing in acetic acid-induced colitis. Human clinical trials for IBD using calendula have not been published.

Chamomile (Matricaria chamomilla) has traditional use in European herbal medicine for inflammatory GI conditions including IBD. It contains apigenin, bisabolol, and chamazulene, which have demonstrated anti-inflammatory and antispasmodic effects relevant to IBD symptom management.

Dandelion (Taraxacum officinale) has traditional use in European and Chinese herbal medicine for inflammatory GI conditions. Its bitter constituents, inulin content, and anti-inflammatory phenolics provide mechanistic rationale for IBD benefit. Preclinical studies demonstrate anti-colitis effects.

Goldenseal is used traditionally for inflammatory conditions of the gastrointestinal tract, and berberine has been studied in preclinical IBD models. No rigorous human clinical trials have evaluated goldenseal preparations specifically for IBD.

Guggulsterone inhibits NF-κB, a central signaling pathway in IBD pathogenesis, in preclinical models. Animal experiments with Z-guggulsterone in colitis models show reduced clinical symptoms and mucosal inflammation. No human clinical trials for IBD with guggul have been published.

Licorice root has traditional use in multiple medical systems including TCM, Ayurveda, and European herbal medicine for inflammatory GI conditions. Its active constituents glycyrrhizin and glycyrrhetinic acid have anti-inflammatory and mucosal protective effects. Some clinical evidence supports its use in GI inflammatory conditions.

Marshmallow root (Althaea officinalis) has traditional herbal use for inflammatory gastrointestinal conditions. Its mucilage content soothes and coats irritated intestinal mucosa, relevant to IBD. Traditional European herbal pharmacopoeias recognize its use for gastric and intestinal inflammation.

Slippery Elm (Ulmus rubra) has a long traditional use history among Native American tribes and Western herbalists for soothing inflammatory gastrointestinal conditions including IBD. Its mucilage content forms a gel that coats the intestinal mucosa. Modern scientific evidence for IBD is limited to small pilot studies and extrapolation from demulcent properties.

Triphala is documented in Ayurveda for inflammatory bowel conditions and has anticolitic effects attributed to antioxidant properties in preclinical models. Its polyphenols restore intestinal epithelial integrity and suppress inflammatory mediators relevant to IBD. Dedicated human clinical trials in IBD populations are lacking.